TILS

invIOs to present at Biotech Showcase

Retrieved on: 
星期三, 十二月 14, 2022
Conference, Immunotherapy, Gesellschaft mit beschränkter Haftung, Biotechnology, CMSO, Epic, Cancer, TILS, Gene expression, IO, Glioblastoma, Patient, Pharmaceutical industry, Medical imaging

VIENNA, Austria, Dec. 14, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter Llewellyn-Davies will present a corporate update during the upcoming Biotech Showcase 2023 meeting in January.

Key Points: 
  • VIENNA, Austria, Dec. 14, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter Llewellyn-Davies will present a corporate update during the upcoming Biotech Showcase 2023 meeting in January.
  • Peter and CMSO Dr Romana Gugenberger are available for meetings with potential investors and partners in San Francisco during the Biotech Showcase / JP Morgan Healthcare Conference week.
  • Details of the invIOs presentation at Biotech Showcase are as follows:
    invIOs is a privately held biotech company based in Vienna, Austria, focusing on the discovery and development of innovative cancer immunotherapies.
  • Once clinically validated, this novel concept will allow access to and treatment for indications not previously addressable by immunotherapy.

Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce

Retrieved on: 
星期四, 十二月 8, 2022
Ovary, TIL, Head, Renal cell carcinoma, Tumor microenvironment, Failure, Ovarian cancer, TME, Safety, Cancer, TILS, Large-cell lung carcinoma, Workforce, Research, Cervical cancer, Costar, COVID-19, Patient, Lead, Pharmaceutical industry, Medical imaging, Instil, DALLAS, NSCLC

The Company expects to report data from the dose escalation cohorts of the Phase 1 ITIL-306 study in 2023.

Key Points: 
  • The Company expects to report data from the dose escalation cohorts of the Phase 1 ITIL-306 study in 2023.
  • Instil is undertaking a reduction in its U.S. workforce of approximately 60% to re-align its operating model from a registration-focused company to a development-stage company.
  • Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing next-generation TIL therapies for the treatment of patients with cancer.
  • Instil is advancing its lead CoStAR-TIL product candidate, ITIL-306, a next-generation, genetically-engineered TIL therapy for multiple solid tumors.

Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment

Retrieved on: 
星期三, 十二月 7, 2022
Immunotherapy, Breast cancer, MOA, Pembrolizumab, HMC, American Cancer Society, Patient, Breast, G1 Therapeutics, Tumor microenvironment, Translational medicine, Neoplasm, Regulatory T cell, II, Trilaciclib, PARK, HER2, Safety, RESEARCH, Cancer, Bladder cancer, TILS, Chain reaction, Progesterone, TNBC, Taxane, PBMC, Research Triangle Park, Carboplatin, Survival, Lung, Risk, CXCL10, Radiation, Immune system, Syngenic, SITC, Therapy, Antigen presentation, Pharmaceutical industry, Vaccine, Medical imaging, Palladium

These initial study results are being presented in a poster session at the annual San Antonio Breast Cancer Symposium (SABCS), December 6 - 10, 2022.

Key Points: 
  • These initial study results are being presented in a poster session at the annual San Antonio Breast Cancer Symposium (SABCS), December 6 - 10, 2022.
  • “These are the first data to show the beneficial effect of a single dose of trilaciclib, one week after administration, on the tumor microenvironment.
  • Results one week after a single dose of trilaciclib show a trend toward an increased ratio of CD8+ T-cells to Tregs within the tumor microenvironment, indicating trilaciclib may favorably modulate the composition of immune cells to support antitumor immune responses.
  • Patients then received a single dose of monotherapy (240 mg/m2) trilaciclib, followed by a tumor biopsy approximately one week later to assess the ability of a single dose of trilaciclib monotherapy to favorably alter the tumor microenvironment.

Turnstone Biologics Enters Cooperative Research and Development Agreement with the National Cancer Institute to Study TIL Therapy in Combination with Viral Immunotherapy

Retrieved on: 
星期二, 十一月 29, 2022
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, NCI, TIL, National Cancer Institute, TILS, Lymphocyte, Patient, CRADA, Potyvirus, Neoplasm, Selection, Cancer, NIH, Cooperative research and development agreement, Development, Immunotherapy, Pharmaceutical industry, Vaccine, Medical imaging, Turnstone

The combination of Selected TILs and viral immunotherapy have the potential to enhance the efficacy of TILs and to extend their benefit to patients with a broad array of solid tumors.

Key Points: 
  • The combination of Selected TILs and viral immunotherapy have the potential to enhance the efficacy of TILs and to extend their benefit to patients with a broad array of solid tumors.
  • I believe TIL therapy is one of the most exciting areas of modern research in the cancer arena, notes Dr. Abbot.
  • Turnstones combination strategies with TIL and viral immunotherapy are designed to improve TIL harvest and overcome the immunosuppressive tumor microenvironment for better trafficking and expansion of our Selected TILs.
  • Turnstone is developing additional strategies to further potentiate the clinical benefit of Selected TILs, including use in combination with their novel viral immunotherapy.

Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
星期一, 十一月 14, 2022
Costar, Observation, Head, TIL, Professor, Research and development, University, TILS, Large-cell lung carcinoma, Patient, Tumor microenvironment, Oncology, Instil, Sale, Cancer, Two-phase electric power, Development, FDA, Pharmaceutical industry, Lithium, Research

Third Quarter 2022 Highlights and Anticipated Milestones:

Key Points: 
  • Third Quarter 2022 Highlights and Anticipated Milestones:
    DELTA-1 manufacturing and regulatory update: As previously announced, enrollment in DELTA-1 was voluntarily paused following the observation of decreased rates of successful manufacturing of ITIL-168.
  • In conjunction with this pause, we are also evaluating opportunities to increase the robustness of our manufacturing process.
  • We plan to provide an update on our ITIL-168 clinical development program in the first quarter of 2023.
  • DELTA-2 clinical update: The Company is deferring enrollment in the DELTA-2 study to focus resources toward higher-priority clinical programs.

Biosimilar Lymphocyte Modulator Global Market Report 2022: Featuring Pfizer, Biogen, Genentech, Novartis & Celltrion - ResearchAndMarkets.com

Retrieved on: 
星期一, 十一月 14, 2022
Health, General Health, Multiple myeloma, Immunotherapy, TILS, TALEN, Radiation, Breast cancer, Psoriasis, Approximation error, Enterocolitis, Lymphoma, George Washington University School of Medicine & Health Sciences, TIL, Disease, Washington University School of Medicine, Leukemia, Biosimilar, Methotrexate, CLL, USFDA, Society, Immune system, Alemtuzumab, Physician, Arthritis, Lymphatic system, Efalizumab, Diabetes, Growth, Multiple sclerosis, Etoposide, Patient, Health, Generic drug, Pharmaceutical industry, Cellectis

The "Biosimilar Lymphocyte Modulator Global Market Report 2022: By Drug, By Disease" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimilar Lymphocyte Modulator Global Market Report 2022: By Drug, By Disease" report has been added to ResearchAndMarkets.com's offering.
  • The main types of drugs in biosimilar lymphocyte modulator are campath-1H, natalizumab biosimilar, efalizumab - A1089-anti-CD11A biosimilar, anti-CD38 daratumumab biosimilar, anti-CS1 elotuzumab biosimilar.
  • The different diseases include arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, psoriasis, others
    Immunotherapy combined with other cancer treatments is expected to drive the growth of the biosimilar lymphocyte modulators market.
  • The shortage of raw material for lymphocyte modulator drugs is expected to restrict the growth of the biosimilar lymphocyte modulator market.

OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma

Retrieved on: 
星期二, 十一月 15, 2022
SAN, SEC, Hyponatremia, Society, Immunotherapy, Recurrence, PR, ORR, MD, RECIST, Neoadjuvant therapy, IVA, Patient, IL-12, Forward-looking statement, PMR, Risk, Nivolumab, Safety, Senior, Translation, TILS, Interim, Company, Chain reaction, Melanoma, IST, PD, Annual report, Death, Private Securities Litigation Reform Act, CD8, EP, CR, NASDAQ, H. Lee Moffitt Cancer Center & Research Institute, Electroporation, Toxicity, SITC, Immune system, SD, Tumor microenvironment, PD-L1, U.S. Securities and Exchange Commission, TIS, Compugen (Israeli company), Drug, Securities & Exchange Commission of Pakistan, Poster, Pharmaceutical industry

This IST is evaluating TAVO, OncoSec's proprietary interleukin 12 (IL-12) encoding plasmid delivered by intratumoral electroporation (TAVO-EP), in combination with intravenous nivolumab.

Key Points: 
  • This IST is evaluating TAVO, OncoSec's proprietary interleukin 12 (IL-12) encoding plasmid delivered by intratumoral electroporation (TAVO-EP), in combination with intravenous nivolumab.
  • The poster entitled, "Neoadjuvant Immunotherapy with intratumoral tavokinogene telseplasmid (TAVO) plus electroporation (EP) in combination with intravenous nivolumab in patients with operable locoregionally advanced melanoma", is available on OncoSec's website.
  • Following the neoadjuvant treatment period, surgery was performed and adjuvant nivolumab was continued for up to 1 year.
  • "We are encouraged with these early data in neoadjuvant melanoma because the expected pathological CR rate with single agent nivolumab in this treatment setting is around 30%.

invIOs presents positive patient data from ongoing Phase 1b trial of APN401 cell therapy in advanced solid tumors at SITC 2022

Retrieved on: 
星期四, 十一月 10, 2022
GLOBE, Thomas Jefferson National Accelerator Facility, IO, Immunity, Escape Room, Convention center, Poster, Medical University of Vienna, Immunotherapy, Cancer, Department, Gesellschaft mit beschränkter Haftung, Serology, MTD, Glioblastoma, Boston Convention and Exhibition Center, TILS, Alveolar soft part sarcoma, Safety, Gene expression, CMSO, Sirna, SITC, Disease, Neoplasm, Clinical trial, Cell, Liver, Biotechnology, Medical school, Patient, Immune system, Peritoneum, Index (publishing), Hematological Cancer Research Investment and Education Act, Society, Transfusion medicine, Vaccine, Pharmaceutical industry, Medical imaging, Epic

Following tumor resection and 11 lines of prior systemic therapy, the patient was enrolled in the ongoing Phase 1b trial presenting with progressive disease.

Key Points: 
  • Following tumor resection and 11 lines of prior systemic therapy, the patient was enrolled in the ongoing Phase 1b trial presenting with progressive disease.
  • Treatment with APN401 was well tolerated and the patient presented with stable disease for 27 weeks, suggesting immunological anti-tumor activity resulting from treatment with APN401.
  • This supports the potency of APN401 and its potential as an effective therapeutic for malignancies, which is being further investigated in the ongoing clinical trial.
  • APN401 is currently being evaluated in a Phase 1b clinical trial in patients with advanced solid tumors.

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results

Retrieved on: 
星期三, 十一月 9, 2022
IND, Adult, Pharming, Therapeutic index, Partnership, Immunotherapy, Research, Biology, G&A, Therapy, VLS, Program, Cell, Administration, Melanoma, Patent, Veterans Health Administration Office of Research and Development, Tumor microenvironment, Food, SEC, Compte rendu, U.S. Securities and Exchange Commission, Time, T cell, Cancer, Liver, Patient, Private Securities Litigation Reform Act, PK, Cytokine, PEGS, Neoplasm, Mouse, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, TILS, Toxicity, Clinical trial, Biotechnology, Society for Immunotherapy of Cancer, Memory, Society, FDA, GLOBE, Primate, Renal cell carcinoma, Goal, Safety, IL-2, NK, TME, CD8, Vaccine, Pharmaceutical industry, Medical imaging, Clothing, Management

WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress, business updates and reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress, business updates and reported financial results for the third quarter ended September 30, 2022.
  • Research& Development (R&D) Expenses: R&D expenses were $13.0 million for the third quarter of 2022, compared to $10.5 million for the third quarter of 2021.
  • General& Administrative (G&A) Expenses: G&A expenses were $7.2 million for the third quarter of 2022, compared to $5.5 million for the third quarter of 2021.
  • Net Loss: Net loss was $19.8 million for the third quarter of 2022, compared to $16.3 million for the third quarter of 2021.

Marengo Therapeutics Presents Preclinical Data Supporting Clinical Investigation of its Lead Asset, STAR0602, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
星期四, 十一月 10, 2022
IO, IV, TEM, TCR, ENA, Tumor microenvironment, Annual general meeting, Immunotherapy, Multimedia, Society for Immunotherapy of Cancer, ATP, Therapy, Phenotype, TILS, PD-1, Cancer, Pharmacology, Cell, MBA, TCM, STAR, Patient, Immune system, TME, Symposium, Society, NHP, TMB, SITC, PD, Pharmaceutical industry, Vaccine

The data disclosed also includes extensive characterization pharmacokinetic (PK) and pharmacodynamic (PD) relationships of STAR0602 in NHP studies.

Key Points: 
  • The data disclosed also includes extensive characterization pharmacokinetic (PK) and pharmacodynamic (PD) relationships of STAR0602 in NHP studies.
  • "We are pleased to present a compelling body of preclinical data that builds on the initial proof-of-concept data shared during our Plenary Oral presentation at the recent 34th EORTC-NCI-AACR (ENA) Symposium last month."
  • Marengo Therapeutics, Inc, an ATP company, is pioneering first-in-class therapeutics that activate the right immune response to promote lifelong protection against cancer.
  • This molecule has shown remarkable single agent activity in a vast array of preclinical models.